{"nctId":"NCT01469039","briefTitle":"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia","startDateStruct":{"date":"2011-12"},"conditions":["Schizophrenia"],"count":623,"armGroups":[{"label":"ALKS 9072","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 9072"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ALKS 9072","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of schizophrenia according to DSM-IV-TR criteria\n* Has been able to achieve outpatient status for more than 3 months in the past year\n* Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)\n* Resides in a stable living situation\n* Willing and able to be confined to an inpatient study unit for 2 weeks or longer\n\nExclusion Criteria:\n\n* History of poor or inadequate clinical response to treatment with aripiprazole\n* History of treatment resistance\n* Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)\n* Diagnosis of current substance dependence (including alcohol)\n* Pregnant, lactating, or breastfeeding\n* Receipt of any antipsychotic medication by IM injection within 60 days before Screening\n* Current involuntary hospitalization or incarceration\n* Hospitalized for more than 30 days during the 90 days before Screening\n\nAdditional inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score","description":"The PANSS scale contains 30 questions, each containing an answer range of 1-7. A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.9","spread":"1.39"},{"groupId":"OG001","value":"-21.8","spread":"1.35"},{"groupId":"OG002","value":"-9.8","spread":"1.39"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Improvement (CGI-I) Scores at Day 85","description":"The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the study. Results indicate participants evaluated at one of the following categories: \"1: very much improved\"; \"2: much improved\"; \"3: minimally improved\"; \"4: no change\"; \"5: minimally worse\"; \"6: much worse\"; or \"7: very much worse\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":207},"commonTop":["Insomnia","Akathisia","Headache","Schizophrenia","Anxiety"]}}}